Tocagen Inc

Tocagen — Investor Presentation (October 2018)

38 slides from Tocagen's investor presentation, Oct 9, 2018

  1. Slide 1: A Cancer-Selective Gene Therapy Company

    A Cancer-Selective Gene Therapy Company Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements about Tocagen Inc. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “should,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intended to identify

  3. Slide 3: Tocagen At-A-Glance

    Tocagen At-A-Glance San Diego, California biotechnology company with ~75 employees Founded in 2007 by pioneers of gene therapy Vision: No One Should Die Of Cancer Core technology is a differentiated retroviral replicating vector (RRV) platform Lead program in fully-enrolled pivotal Phase 3 trial und

  4. Slide 4: Executive Team with a Proven Track Record

    Marty J. Duvall Chief Executive Officer Mark Foletta EVP & Chief Financial Officer Asha Das, M.D. SVP & Chief Medical Officer Doug Jolly, Ph.D. Founder, EVP, Research and Pharm Development Harry Gruber, M.D. Founder, President Science and Innovation Executive Team with a Proven Track Record

  5. Slide 5: Cancer-Selective Gene Therapy is in Our Name

    Cancer-Selective Gene Therapy is in Our Name … TO CAncer GENe EXPLORE EXECUTE Achieve POC in other solid tumors with Toca 6 Investigate new opportunities using RRV platform Leverage Phase 1 data: CRs and survival Move Toca 511 & Toca FC to front-line HGG Advance opportunity in key geographies EXPAND

  6. Slide 6: Technology Platform

    Technology Platform

  7. Slide 7: Retroviral Replicating Vector (RRV) Gene Therapy Platform

    Retroviral Replicating Vector (RRV) Gene Therapy Platform Selective Infection, Spread and Persistence in Cancer Cells RRVs Infect Immune Deficient Cancer Cells But Not Normal Cells With Intact Immune Systems Cancer cell interferon pathway genetic defects reduce anti-retroviral resistance Does Not In

  8. Slide 8: Non-Lytic Virus Infects and Persists Selectively in Cancer Cells

    Non-Lytic Virus Infects and Persists Selectively in Cancer Cells RRV Platform Can Deliver a Variety of Therapeutic Genes IL-2 IL-12 IL-15 αPD-L1 (Toca 521) Cytosine deaminase (Toca 511) with prodrug (Toca FC) Thymidine kinase Purine nucleoside phosphorylase Anti-PD-L1 OX40L scFv ab Cytokines Enzymes

  9. Slide 9: Tocagen Pipeline

    Candidate Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Toca 511 & Toca FC Recurrent high grade glioma Advanced solid tumors (CRC, Melanoma, Pancreatic, Lung & Breast) Newly diagnosed high grade glioma Toca 521 Oncology RRV-Anti-PD-L1 Tocagen Pipeline 1st interim analysis completed August

  10. Slide 10: Lead Program

    Lead Program Toca 511 & Toca FC

  11. Slide 11: Lead Program - Immune Activation Via the Tumor Microenvironment

    Lead Program - Toca 511 & Toca FC Immune Activation Via the Tumor Microenvironment 5-FU also eliminates immunosuppressive myeloid cells (MDSCs and TAMs), activating antitumor immunity Gamma retrovirus Toca 511 selectively infects tumor, persists and spreads through tumor while delivering the CD gene

  12. Slide 12: Toca & 5-FC Activates a Durable Anti-Cancer Immune Response

    Toca 511 & 5-FC Activates a Durable Anti-Cancer Immune Response Locally, within tumor microenvironment, Toca 511 & Toca FC alter immune profile Increased T cell immune infiltrates in tumor (COLD → HOT) Immune effects are CD4 & CD8 T cell-dependent and correlate with immune-suppressive myeloid cells

  13. Slide 13: Toca & 5-FC Activate Immune System in Tumor Micro-Environment

    Toca 511 & 5-FC Activate Immune System in Tumor Micro-Environment Preclinical Mouse Glioma Model TAM: tumor associated macrophages; MDSC: myeloid derived suppressor cells Increase in immune activating lymphoid cells Decrease in immune suppressive myeloid cells Mitchell et al. Neuro-Oncology, 2017 T-

  14. Slide 14: Executing in recurrent High Grade Glioma

    Executing in recurrent High Grade Glioma

  15. Slide 15: Development in HGG: A Deadly and Aggressive Disease

    Recurrent High Grade Glioma (rHGG) Newly diagnosed GBM Standard of care includes surgery, radiation, temozolomide mOS from initial diagnosis to death ~16 months Limited treatment options Development in HGG: A Deadly and Aggressive Disease Newly diagnosed GBM Recurrent GBM or AA Brain tumor by MRI Su

  16. Slide 16: Key Differentiators in Brain Cancer

    Key Differentiators for Toca 511 & Toca FC in Brain Cancer Preclinical MOA, CR’s, OS data supported BTD and PRIME designations and peer-reviewed publications Notorious blood brain barrier mitigated with local Toca 511 delivery and precedent for 5-FC to treat brain fungus Multiple mechanisms support

  17. Slide 17: Phase 1 Experience in rHGG Patients

    Phase 1 Experience in 127 rHGG Patients RESECTION Injection into cavity wall after tumor debulking n=56 INTRATUMORAL Direct injection into the brain tumor n=54 INTRAVENOUS Injection IV prior to resection and into cavity wall at resection n=17 Favorable safety profile Increased survival vs historic b

  18. Slide 18: Phase 1 Resection Study – Patients had Advanced Disease

    Population All Patients N=56 Toca 5 Dose and Entry Criteria Subset N=23 Median Age (range) 56 (24-75) 55 (24-70) n (%) n (%) Male 43 (77) 20 (87) Karnofsky Performance Score 70-80 90-100 17 (30) 39 (70) 5 (22) 18 (78) Initial Tumor Histology GBM Anaplastic Astrocytoma Other gliomas 46 (82) 6 (11) 4

  19. Slide 19: Adverse Events Related to Toca 511 and Toca FC

    Treatment-Related AEs Toca 511 & Toca FC N=127 Grade 1/2 Grade 3/4 n (%) n (%) Any treatment-related event 62 (48.8) 11 (8.7) Treatment-related event ≥5% patients Fatigue 37 (29.1) 1 (<1) Diarrhoea 17 (13.3) 1 (<1) Nausea 14 (11.0) 0 Headache 8 (6.2) 1 (<1) Decreased appetite 7 (5.5) 0 Data cutoff 0

  20. Slide 20: Phase 1 Resection Study: Survival Exceeds Historical Data

    Population Toca 511 & Toca FC Resection Study Median Overall Survival Months1 Historical Data in Recurrent Disease Recurrent High Grade Glioma 12.4 (n=43) 7.2 (n=110)2 Recurrent High Grade Glioma and higher doses 13.2 (n=30) 7.2 (n=110)2 Higher doses and Toca 5 entry criteria3 14.4 (n=23) 8.5 (n=437

  21. Slide 21: Phase 1 Resection Study: All 6 Responders Are Durable Complete Responders

    Response Category1 All Efficacy Evaluable Patients N=532 Higher Doses and Toca 5 Entry Criteria Subset3 N=23 Durable response rate (CR or PR ≥ 24 weeks), n (%) 6 (11.3); All CRs 5 (21.7); All CRs Median duration of durable response Not reached (median follow-up 36.5 mos) Not reached (median follow-u

  22. Slide 22: Phase 1 Resection Study: Long-Term Survival in Higher Dose Cohort

    AA, IDH1 mt Phase 1 Resection Study: Long-Term Survival in Higher Dose Cohort All Responses are Durable Complete Responses & Associated with Long Term Survival Toca 511-11-01 Overall Survival and the Best Response 1st/2nd Recurrence, No prior bevacizumab, <=5cm, Higher Dose Cohorts (N=23) Data as of

  23. Slide 23: Final Results from Phase I Study in rHGG

    Final Results from Phase I Study of Toca 511 & Toca FC in rHGG Extended survival in patients who meet dose/eligibility criteria for Phase 3 Toca 5 Trial Cloughesy et al. JSGCT, 2018 Data cut off 20 Dec 2017 Estimated Probability of Survival (KM) Time (Months) + Censored Numbers at Risk: Median follo

  24. Slide 24: Complete Response in a Patient with Progressive GBM, IDH1 wt

    Complete Response in a Patient with Progressive GBM, IDH1 wt Adapted from Cloughesy et al. Neuro-Oncol, 2018. In Press. CR by independent Radiology Review, Macdonald criteria Toca FC cycle is every 6 weeks tumor progression resection of enhancing tumor tumor progression (baseline for measurement ) s

  25. Slide 25: Toca 5 Pivotal Phase 3 Trial

    Primary Endpoint: Overall Survival Exploratory Secondary Endpoint: Durable Response Rate Toca 5 Pivotal Phase 3 Trial – Patient Follow-up Ongoing One of the largest trials in rHGG with enrollment completed Sept 2018 Eligibility GBM or AA First and 2nd recurrence Tumor ≤ 5cm ClinicalTrials.gov Identi

  26. Slide 26: Statistical Plan Set for Two Analyses of Overall Survival

    Statistical Plan Set for Two Analyses of Overall Survival in Next 15 Months Toca 5 Pivotal Phase 3 Trial – Patient Follow-up Ongoing Multiple Opportunities to “Win” in 2019 Toca 5 Trial - Statistical Overview Patients: 380 Primary endpoint: Overall Survival MOA- Driven exploratory endpoint: Durable

  27. Slide 27: Launch Planning Ongoing

    Pricing commensurate with value delivered and expected to be inline with reference immunotherapy drugs Commercial and medical affairs footprint to target ~80 high volume sites, majority of which have participated in Toca 511 & Toca FC development Recurrent High Grade Glioma continues to be a disease

  28. Slide 28: Expanding to realize potential of Toca

    Expanding to realize potential of Toca 511 & Toca FC

  29. Slide 29: Newly Diagnosed HGG Opportunity

    Newly Diagnosed HGG Opportunity Toca 511 injection at time of regular surgical resection Standard resection recovery time allows for viral spread Potential amplification of effect of temozolomide + radiation Newly diagnosed GBM Recurrent GBM or AA Brain tumor by MRI Stupp Regimen: Surgery, radiation

  30. Slide 30: Global HGG Opportunity

    Toca 511 & Toca FC - Global HGG Opportunity Geography Development and Regulatory Status Breakthrough Therapy Designation Orphan and Fast Track designations Pivotal Phase 3 study (Toca 5) ongoing Commercial readiness planning underway PRIME and Orphan Designations EMA supportive of Toca 5 study as ba

  31. Slide 31: Slide 31

  32. Slide 32: Complementary MOA and Favorable Safety Supports Combinations

    Complementary MOA and Favorable Safety Supports Combinations Brain cancer Colorectal cancer Pancreatic cancer Breast cancer Bladder cancer Prostate cancer Ovarian cancer Toca 511 & Toca FC Preclinical Efficacy is Supported Across a Range of Solid Tumors NOTE: The images above are from clinical sampl

  33. Slide 33: Durable Responses and Anti-Tumor Immune Memory in mCRC Model

    Durable Responses and Anti-Tumor Immune Memory in mCRC Model Cancer-selective expression of transgene after IV administration of Toca 511 MOA involves depletion of MDSCs Survival in ~60% of treated mice Induction of systemic anti-tumor immunity No dose limiting systemic lympho- or myelo-toxicity Toc

  34. Slide 34: Ongoing Phase 1b Trial in Advanced Solid Tumors

    Ongoing Phase 1b Trial in Advanced Solid Tumors Design Phase 1b, multicenter, open label (up to 30 patients) Patients with advanced solid tumors or lymphoma Patients qualified based on presence of specific molecular characteristics and specific tumor types Latest Results at CRI-CIMT-EATI-AACR Intern

  35. Slide 35: Toca 521: Cancer Selective Gene Therapy Targeting PD-L1

    Toca 521 Inhibits Tumor Growth and Elicits Immune Memory Function in Tu-2449SC Mouse Model Toca 521: Cancer Selective Gene Therapy Targeting PD-L1 From Within Recent presentation at 2018 American Society of Gene & Cell Therapy Meeting (ASGCT) Toca 521 (RRVscFv-PD-L1) selectively infects cancer cells

  36. Slide 36: Summary

    Summary

  37. Slide 37: Financial Position and Near-Term Catalysts

    Financial Position and Near-Term Catalysts Cash, cash equivalents and short-term investments (as of June 30, 2018): $79.5M Estimated cash burn in 2018: ~$50M, end-2018 cash balance: ~$70M (up from ~$40M guidance) Debt restructure in May with Oxford Capital and Silicon Valley Bank added ~$18M to cash

  38. Slide 38: Looking Forward to Achieving More Milestone Moments

    Looking Forward to Achieving More Milestone Moments … Thank you to all of the patients and families who have supported our work. Financial support also provided by:

Tocagen — Investor Presentation (October 2018) on 6ix